ISSN: 2320-7159
IJMR
INTERNATIONAL JOURNAL OF MEDICAL RESEARCH

*NARRATIVE REVIEW*

# Long-COVID: Current Understanding and Future Directions

**Deepak Shukla**[1]

[1]Department of Internal Medicine, SMIMER, Surat, India

Dr. Deepak Shukla (Email: shukla76@yahoo.com)

**DOI:** https://doi.org/10.55489/ijmr.1301202577



**Citation:** Shukla D. Long-COVID: Current Understanding and Future Directions. Intl J Med Res 2025;13(1):4-13. DOI: 10.55489/ijmr.1301202577

**Received:** November 29, 2024
**Accepted:** December 23, 2024
**Published:** January 01, 2025



**Funding:** Non-Declared.

**Conflict of interests:** The authors have declared that no conflict of interests exists.

**Publisher:** Medsci Publications, India

## ABSTRACT

Long-COVID, or post-acute sequelae of SARS-CoV-2 infection, represents a significant global health challenge characterized by persistent symptoms lasting months after acute COVID-19. This narrative review synthesizes current understanding, exploring epidemiology, pathophysiology, clinical manifestations, diagnosis, management, and future directions. Prevalence estimates suggest 10-30% of survivors experience Long-COVID, with higher rates in women, middle-aged adults, and those with severe initial infections. Proposed mechanisms include viral persistence, immune dysregulation, endothelial dysfunction, and multi-organ damage, though causality remains uncertain due to observational study limitations. Common symptoms-fatigue, dyspnea, cognitive impairment, and joint pain-span systemic, respiratory, cardiovascular, and neurological domains, severely impacting quality of life. Diagnosis relies on clinical history and exclusion of differentials, lacking specific biomarkers. Management is symptom-focused, involving multidisciplinary rehabilitation, pacing, and emerging pharmacological trials, though evidence is limited by small sample sizes and biases. Future research prioritizes standardized definitions, longitudinal studies, and biomarker discovery to enable targeted therapies. Public health strategies must address inequities and integrate surveillance. Despite advances, gaps in understanding prognosis and treatment persist, necessitating increased funding and interdisciplinary collaboration to mitigate Long-COVID's long-term burden and inform pandemic preparedness.

**Keywords:** Long-COVID, Post-acute sequelae, SARS-CoV-2, Persistent symptoms, Pathophysiology, Multidisciplinary management

## Introduction

Long-COVID, also known as post-acute sequelae of SARS-CoV-2 infection (PASC), refers to a constellation of symptoms persisting or emerging beyond the acute phase of COVID-19, typically lasting at least three months after the initial infection. According to the Centers for Disease Control and Prevention (CDC), it is defined as a chronic condition following SARS-CoV-2 infection, present for at least three months, with symptoms that can be continuous or relapsing [1]. The World Health Organization (WHO) specifies that symptoms usually start within three months of the initial illness and last at least two months, often without alternative explanations [2]. This narrative review synthesizes the evolving understanding of Long-COVID as of 2025, drawing from epidemiological data, pathophysiological insights, clinical manifestations, diagnostic approaches, management strategies, and future research priorities. We critically appraise the literature, highlighting biases such as selection bias in cohort studies (e.g., overrepresentation of hospitalized patients), small sample sizes in early trials, and reliance on self-reported symptoms, which may inflate prevalence estimates or introduce recall bias. Evidence quality varies; while large meta-analyses provide moderate-to-high certainty, many mechanistic studies are observational with low generalizability.

Historically, Long-COVID emerged during the 2020 pandemic, initially termed by patient communities as "long-haulers" [3]. By mid-2020, reports documented persistent symptoms in non-hospitalized cases, challenging early assumptions that recovery was swift for mild infections [4]. Terminology evolved from informal descriptors to formalized definitions by 2021, with the National Academies of Sciences, Engineering, and Medicine (NASEM) in 2024 describing it as a "chronic, systemic disease state with profound consequences" [5]. This shift reflects growing recognition of its multisystem impact. Public health significance is immense: globally, a 2022 meta-analysis estimates a pooled prevalence of 36% among COVID-19 survivors, with economic burdens from lost productivity and healthcare costs exceeding billions annually [6]. In the U.S., 7.2% of adults report Long-COVID, disproportionately affecting women and middle-aged groups [7]. Critically, early studies suffered from heterogeneous definitions, leading to inconsistent prevalence reports; standardized criteria have improved evidence quality but highlight gaps in underrepresented populations.

The purpose of this review is to provide a balanced synthesis, noting high-quality evidence from randomized controlled trials (RCTs) on interventions while critiquing observational data for confounding factors like vaccination status. We emphasize unresolved controversies, such as the role of viral persistence versus autoimmunity, and advocate for interdisciplinary approaches.

## Epidemiology and prevalence

Prevalence of Long-COVID varies widely due to definitional inconsistencies and study designs, with a global pooled estimate of 36% among COVID-19 survivors from a 2022 meta-analysis of 429 studies [6]. Another 2022 meta-analysis of 50 controlled studies reported risks for diverse symptoms, with fatigue and dyspnea being common [8]. In the U.S., 7.2% of adults are affected, with higher rates among women (potentially due to reporting bias) and those aged 35-49 [7]. Globally, a multinational study across 14 nations found 25-30% prevalence, higher in lower-middle-income countries (29.8%) versus high-income ones (14.4%), possibly reflecting healthcare access disparities and selection bias in surveys [9]. Among children, estimates are lower (4-10%), but underreporting due to milder symptoms is a concern [10].

Risk factors include severe initial infection, hospitalization, female sex, comorbidities like diabetes and obesity, and unvaccinated status [11]. Vaccination reduces risk by 50-70%, per meta-analyses, though evidence is moderate due to observational designs prone to confounding by health-seeking behavior [12]. Variants influence prevalence; Omicron shows lower rates (3-5%) than Delta (10-20%), but reinfections increase cumulative risk [13]. Demographic disparities persist: ethnic minorities and low-socioeconomic groups report higher rates, likely due to exposure biases and limited access to care, though studies often lack diverse cohorts, introducing generalizability issues [14].

Trends indicate stabilization post-vaccination eras, but electronic health record (EHR) analyses from 2023 show 10-26% of adults and 4% of children affected long-term [15]. Critically, many estimates rely on self-reports, risking overestimation; objective cohort studies like RECOVER provide higher-quality data but are resource-intensive, limiting scalability. Conflicts arise from pooled subtypes (e.g., respiratory vs. neurological), with a 2021 review estimating 20% for fatigue and respiratory subtypes [16]. Overall, evidence quality is moderate, with meta-analyses strengthening causal inferences but highlighting needs for longitudinal, diverse studies.

## PATHOPHYSIOLOGY AND MECHANISMS

The pathophysiology of Long-COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC), is complex and multifactorial, characterized by a constellation of mechanisms that remain incompletely elucidated. Current evidence points to four primary drivers: viral persistence, immune dysregulation, endothelial dysfunction, and multi-organ damage, each contributing to the heterogeneous clinical presentations of Long-COVID [17]. These mechanisms interact dynamically, potentially amplifying one another, and their relative contributions vary across patients, complicating mechanistic clarity.

A comprehensive 2022 review underscores immune-mediated processes as central to Long-COVID, with autoimmunity and cytokine dysregulation playing pivotal roles [18]. Elevated inflammatory markers, such as interleukin-6 (IL-6), C-reactive protein (CRP), and tumor necrosis factor-alpha (TNF-α), are consistently observed in Long-COVID patients, suggesting a chronic pro-inflammatory state. These markers correlate with symptom severity, particularly fatigue and cognitive impairment, providing moderate-to-high-quality evidence from longitudinal cohort studies. However, the precise triggers of this inflammatory cascade remain unclear, with hypotheses pointing to persistent antigenic stimulation or dysregulated immune signaling.

Viral persistence is a leading hypothesis, with evidence of SARS-CoV-2 RNA or proteins detected in tissues such as the gastrointestinal tract, brain, and lymphoid organs months post-infection [19]. This persistence may sustain chronic inflammation, potentially through low-level viral reservoirs that evade immune clearance. However, detection is limited by assay sensitivity and specificity, introducing potential detection bias, as polymerase chain reaction (PCR) and immunohistochemistry vary in their ability to distinguish replicating virus from non-infectious remnants. Animal models, including hamsters and mice, demonstrate persistent viral RNA in tissues without active replication, suggesting a latent reservoir; yet, human studies are constrained by small sample sizes ($n<100$) and observational designs, which limit causal inferences [20]. These studies often fail to differentiate whether persistent RNA drives symptoms or represents an epiphenomenon, necessitating more robust longitudinal data.

Immune dysregulation encompasses several processes, including T-cell exhaustion, B-cell hyperactivity, and autoantibody production, which are linked to clinical phenotypes such as neurocognitive impairment and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)-like symptoms [21]. A 2022 study highlights neuroinflammatory drivers, including microglial activation and neurotransmitter imbalances (e.g., reduced serotonin and dopamine signaling), which may underlie "brain fog" and cognitive deficits [22]. These findings are supported by elevated cerebrospinal fluid (CSF) cytokines and neuroimaging evidence of white matter changes in Long-COVID patients. However, the evidence quality is low due to cross-sectional study designs, which are prone to reverse causation and cannot establish temporality between inflammation and neurological symptoms. Confounding factors, such as pre-existing neuropsychiatric conditions, further complicate interpretation.

Vascular mechanisms are increasingly recognized as critical, with endothelial dysfunction and microclot formation contributing to systemic symptoms, including thrombosis and organ ischemia [23]. Histopathological studies reveal fibrin-rich microclots and endothelial injury in Long-COVID patients, particularly those with cardiovascular and respiratory symptoms. These findings are supported by elevated D-dimer levels and impaired flow-mediated dilation, indicating vascular compromise. However, biopsy studies are ethically and practically limited, often restricted to severe cases, which introduces selection bias and underrepresents milder presentations. The interplay between endothe-

lial dysfunction and immune activation may create a feedback loop, exacerbating tissue hypoxia and organ damage.

Multi-organ effects are evident across systems, with gut microbiome dysbiosis and mitochondrial dysfunction emerging as key contributors [24]. Alterations in gut microbial diversity, such as reduced butyrate-producing bacteria, correlate with systemic inflammation and fatigue, potentially disrupting the gut-brain axis. Mitochondrial dysfunction, evidenced by reduced ATP production and oxidative stress, is implicated in post-exertional malaise (PEM), a hallmark of Long-COVID. A 2022 review also highlights epigenetic modifications, such as DNA methylation changes in immune and metabolic genes, as potential drivers of persistent symptoms [24]. These epigenetic alterations may explain the variability in symptom duration and severity, though mechanistic studies are limited by small cohorts and lack of functional validation.

Genetic predispositions remain an area of active investigation, with genome-wide association studies (GWAS) identifying variants in immune-related genes, such as those in the HLA and interferon signaling pathways, associated with Long-COVID risk [25]. However, inconsistent replication across diverse populations, due to heterogeneous cohorts and limited sample sizes, hampers generalizability. For instance, GWAS findings from predominantly European cohorts may not apply to other ethnic groups, highlighting the need for inclusive studies. Evidence quality is high for biomarker correlations (e.g., proteomics identifying inflammatory signatures), but low for mechanistic causality, as randomized controlled trials (RCTs) are absent. Methodological biases, including survivor bias in long-term cohorts and overemphasis on severe initial infections, further skew understanding, as milder cases are often underrepresented.

## Clinical manifestations and symptomatology

Long-COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC), presents a broad spectrum of symptoms affecting multiple organ systems, with over 200 distinct manifestations documented in the literature [26]. The most prevalent symptoms include fatigue (affecting approximately 25% of patients), shortness of breath (24%), and joint pain (24%), as identified in a 2021 systematic review of global cohorts [26]. These symptoms vary in intensity and duration, contributing to significant heterogeneity in clinical presentation and posing challenges for standardized assessment.

Systemic symptoms are a hallmark of Long-COVID, with post-exertional malaise (PEM) reported in up to 45% of patients in some prospective cohorts, closely resembling myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) [27]. PEM, characterized by profound exhaustion following minimal physical or cognitive exertion, is often debilitating and distinguishes Long-COVID from other post-viral syndromes. This overlap with ME/CFS is supported by shared immunological and metabolic signatures, such as elevated cytokine levels and mitochondrial dysfunction, though mechanistic studies are limited by small sample sizes and observational designs [27]. Evidence quality for systemic symptoms is moderate, derived from cohort studies, but self-selection bias in patient-reported data may overestimate prevalence.

Respiratory manifestations, particularly persistent dyspnea, affect 20-30% of Long-COVID patients, often linked to microvascular damage and impaired gas exchange [28]. However, pulmonary function tests, such as spirometry, frequently show normal results, suggesting a functional rather than structural etiology, possibly related to dysautonomia or microcirculatory dysfunction. Cohort studies provide moderate-quality evidence for respiratory symptoms, but self-selection bias, particularly in studies relying on patient registries, may skew findings toward more symptomatic individuals [28]. Longitudinal data indicate that dyspnea may persist for over a year in some patients, significantly impacting functional capacity.

Cardiovascular symptoms, including palpitations and orthostatic intolerance, are common and associated with autonomic dysfunction. A 2022 meta-analysis of 15 studies reported elevated risks of cardiovascular events, such as postural orthostatic tachycardia syndrome (POTS) and arrhythmias, extending beyond two years post-infection [29]. These findings are supported by high-quality evidence from large-scale electronic health record (EHR) analyses, which demonstrate increased incidence of cardiovascular mor-

bidity compared to non-COVID controls. However, heterogeneity in diagnostic criteria for POTS and reliance on self-reported symptoms introduce potential bias.

Neurological manifestations, notably "brain fog" and headaches, affect 20-50% of Long-COVID patients, with meta-analyses indicating persistent cognitive deficits, including impairments in memory, attention, and executive function [30]. Small-scale neuroimaging studies (n<50) using MRI and PET scans reveal white matter abnormalities and hypometabolism in brain regions like the prefrontal cortex, but these studies are underpowered, risking type II errors and limiting generalizability [30]. The high prevalence of neurological symptoms underscores their impact on daily functioning, though evidence quality for causality remains low due to confounding factors, such as pre-existing cognitive impairments and stress-related disorders.

Gastrointestinal and musculoskeletal symptoms, including abdominal pain, diarrhea, and myalgia, are reported in 10-20% of patients and frequently overlap with psychological comorbidities, such as anxiety and depression, which affect up to 30% of Long-COVID cohorts [31]. These symptoms are often non-specific, complicating differential diagnosis. High-quality evidence from large international surveys confirms their prevalence, but retrospective study designs introduce recall bias, potentially inflating estimates [31]. Psychological comorbidities may exacerbate physical symptoms, creating a bidirectional relationship that warrants further investigation.

Long-COVID symptoms range from mild to severely debilitating, with cluster analyses identifying distinct clinical phenotypes, such as cardiorespiratory and neurocognitive subtypes [32]. A 2022 study using unsupervised machine learning on self-reported symptoms delineated these clusters, highlighting their prognostic significance [32]. The impact on quality of life is profound, with approximately 38% of patients in international cohorts unable to return to work or resume pre-illness activities due to chronic fatigue and cognitive limitations [33]. Evidence for symptom prevalence is robust, drawn from large-scale surveys and meta-analyses, but causality is less certain due to confounding by pre-existing conditions, such as fibromyalgia or psychiatric disorders. Additional biases include underrepresentation of asymptomatic or mildly affected recoveries, which may skew prevalence estimates toward severe cases, and recall bias in retrospective surveys, which can distort symptom reporting.

## Diagnosis and Assessment

Diagnosing Long-COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC), remains a clinical challenge due to the absence of specific, validated biomarkers, necessitating reliance on detailed clinical history and exclusion of differential diagnoses [34]. The Centers for Disease Control and Prevention (CDC) guidelines prioritize patient-reported symptoms persisting beyond the acute phase of SARS-CoV-2 infection, without mandating a confirmed positive test, acknowledging the potential for false-negative results in PCR or antigen testing, particularly in early pandemic waves [35]. Similarly, the World Health Organization (WHO) and National Institute for Health and Care Excellence (NICE) provide aligned diagnostic criteria, emphasizing symptom duration (typically >2–3 months post-infection) and significant functional impact, with symptoms that cannot be explained by alternative diagnoses [2]. These consensus-based definitions, derived from Delphi processes and expert panels, provide moderate-quality evidence but highlight the need for standardized diagnostic protocols to reduce variability in clinical practice.

Assessment tools are critical for characterizing Long-COVID's impact and guiding management. The Post-COVID Functional Status (PCFS) scale, validated for assessing functional limitations, quantifies disability across domains such as daily activities and mobility, offering a standardized measure for longitudinal tracking [36]. Questionnaires targeting post-exertional malaise (PEM), a hallmark symptom, help differentiate Long-COVID from other fatigue-related conditions, though their specificity is limited by subjective reporting [36]. Diagnostic evaluation often incorporates imaging modalities, such as magnetic resonance imaging (MRI) for neurological symptoms like "brain fog" or cognitive impairment, which may reveal white matter abnormalities or cerebral hypoperfusion. Functional tests, such as the 6-minute walk test, assess exercise capacity and cardiorespiratory function, providing objective metrics to complement patient-reported outcomes [36]. However, evidence for imaging and functional testing is limited by small cohort sizes and inconsistent findings, reducing diagnostic reliability.

Differential diagnosis is complex due to significant overlap with conditions such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), fibromyalgia, and other post-viral syndromes, which share features like fatigue, PEM, and cognitive dysfunction [37]. A multidisciplinary approach, integrating input from specialties such as pulmonology, neurology, and rheumatology, is recommended to systematically exclude alternative causes, including endocrine disorders, autoimmune diseases, and psychiatric conditions [37]. A 2022 clinical compendium emphasizes comprehensive history-taking to evaluate symptom onset, duration, severity, and risk factors (e.g., severe initial infection, female sex, or comorbidities), which informs tailored diagnostic workups [38]. For example, screening for orthostatic intolerance or autonomic dysfunction, common in Long-COVID, may involve tilt-table testing or heart rate variability analysis to identify conditions like postural orthostatic tachycardia syndrome (POTS).

Evidence quality for diagnostic guidelines is moderate, primarily based on expert consensus and observational data, as randomized controlled trials (RCTs) are infeasible for diagnostic validation [34]. Biomarker research, including studies of inflammatory markers like interleukin-6 (IL-6) or C-reactive protein (CRP), shows inconsistent results, with elevated levels in only subsets of patients, limiting their utility as diagnostic tools [38]. These inconsistencies may stem from heterogeneity in patient cohorts, timing of sample collection, and assay variability. Methodological biases further complicate diagnosis: diagnostic delays in primary care settings, often due to limited awareness or access to specialized testing, can lead to underdiagnosis, particularly in underserved populations. Conversely, overpathologization of normal recovery variations risks misattributing transient symptoms to Long-COVID, inflating prevalence estimates. Recall bias in patient-reported symptoms and lack of pre-infection baseline data further confound diagnostic accuracy.

## MANAGEMENT AND TREATMENT APPROACHES

Management of Long-COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC), remains primarily symptom-focused due to the absence of curative therapies, with strategies tailored to the diverse clinical presentations of the condition. Current approaches encompass non-pharmacological interventions, pharmacological trials, and multidisciplinary care, but evidence quality varies widely, and no standardized treatment protocol exists.

Non-pharmacological interventions are the cornerstone of Long-COVID management, with cognitive behavioral therapy (CBT) and structured rehabilitation programs demonstrating moderate benefits in alleviating symptoms such as fatigue and cognitive impairment. A 2024 BMJ systematic review of 97 randomized controlled trials (RCTs) reported small-to-moderate effect sizes for CBT in improving quality of life and psychological symptoms, though high dropout rates suggest selection bias, as patients with severe symptoms may struggle to complete intensive programs [39]. Rehabilitation strategies, including graded exercise therapy (where appropriate) and pacing, help manage post-exertional malaise (PEM) by balancing activity and rest to prevent symptom exacerbation. Physical therapy, tailored to individual functional capacity, improves mobility and cardiorespiratory endurance, while telemedicine platforms enhance access to care, particularly for patients in remote or underserved areas [42]. Multidisciplinary clinics, integrating specialties such as pulmonology, neurology, and psychology, are effective in addressing the multisystem nature of Long-COVID but are often limited by resource constraints, particularly in low- and middle-income settings [42]. Patient-centered care, including peer-led support groups, plays a critical role in addressing psychological distress and social isolation, fostering coping strategies and resilience. Evidence for non-pharmacological interventions is robust, with high-quality RCTs supporting rehabilitation and pacing, though generalizability is limited by variability in intervention protocols and patient adherence.

Pharmacological interventions remain experimental, targeting hypothesized mechanisms such as viral persistence, inflammation, and vascular dysfunction. Repurposed antivirals, such as nirmatrelvir, have shown preliminary promise in small-scale trials ($n<100$) by potentially reducing viral reservoirs, though results are constrained by limited sample sizes and lack of long-term outcomes [40]. Anti-inflammatory agents, such as low-dose corticosteroids, and anticoagulants, like rivaroxaban, are used to address endo-

thelial dysfunction and microclot formation, which contribute to symptoms like dyspnea and palpitations [41]. However, evidence for these treatments is of low quality, derived primarily from observational studies prone to confounding by indication and selection bias, as patients with severe vascular symptoms are more likely to receive these therapies [41]. Emerging trials are exploring novel agents, such as tirzepatide, a GLP-1 receptor agonist, for its potential to mitigate fatigue by improving metabolic function, and monoclonal antibodies like sipavibart, which target residual viral antigens [43]. However, trial failures, such as the BC 007 neutralizing antibody study, highlight methodological flaws, including inadequate statistical power and poorly defined endpoints, underscoring the need for better-designed RCTs [43]. Evidence for pharmacological treatments remains preliminary, with low-to-moderate quality due to early-phase trials and publication bias favoring positive results.

The heterogeneity of Long-COVID phenotypes necessitates personalized treatment approaches, guided by symptom clusters (e.g., cardiorespiratory, neurocognitive). Multidisciplinary clinics facilitate comprehensive care but face challenges in scalability due to high costs and limited specialist availability, particularly in resource-constrained settings [42]. Ongoing research emphasizes the importance of patient-reported outcome measures (PROMs) to evaluate treatment efficacy, though these are subject to recall bias and subjective variability. The lack of validated biomarkers further complicates treatment evaluation, as objective measures of improvement are scarce.

## FUTURE DIRECTIONS

The evolving landscape of Long-COVID research underscores several critical priorities to address unmet clinical and public health needs. A primary focus is the development of standardized diagnostic criteria to reduce heterogeneity in case definitions, which currently complicates prevalence estimates and treatment evaluation [44]. Longitudinal cohort studies, designed with diverse populations and extended follow-up periods, are essential to elucidate the natural history of Long-COVID, including its trajectory, risk factors, and predictors of recovery [44]. Biomarker discovery remains a cornerstone of research efforts, aiming to identify reliable indicators-such as inflammatory cytokines, autoantibodies, or metabolomic profiles-that can facilitate early diagnosis, stratify patients by phenotype, and guide targeted therapies [44]. These priorities are supported by moderate-quality evidence from systematic reviews, though challenges persist due to variability in study methodologies and patient cohorts.

Therapeutic innovation is a key research frontier, with ongoing investigations into immunomodulators (e.g., interleukin inhibitors) and antivirals (e.g., extended-course nirmatrelvir) to address underlying mechanisms like immune dysregulation and viral persistence [45]. Personalized medicine, tailored to distinct Long-COVID phenotypes such as cardiorespiratory or neurocognitive clusters, holds significant promise but remains in early stages, limited by small-scale trials and a lack of validated stratification tools [45]. Preliminary studies suggest that phenotyping based on clinical and molecular characteristics could optimize treatment outcomes, but robust clinical trial data are needed to translate these approaches into practice. Evidence quality for therapeutic advancements is low, constrained by early-phase studies and heterogeneous endpoints.

Public health strategies are critical to mitigating Long-COVID's societal impact. Integrating Long-COVID surveillance into existing health systems, such as electronic health records (EHRs) and national registries, can improve real-time monitoring of prevalence and outcomes, enabling timely resource allocation [46]. Addressing health inequities is paramount, as marginalized populations-disproportionately affected due to higher exposure risks and limited healthcare access-require targeted interventions to ensure equitable care [46]. Emerging technologies, such as artificial intelligence (AI) and machine learning, are being leveraged to predict Long-COVID risk and progression, with models integrating clinical, demographic, and genomic data to identify high-risk individuals [47]. Global collaborations, including initiatives like the WHO's Post-COVID Condition Research Network, foster data sharing and harmonized research protocols, enhancing the generalizability of findings [47]. These efforts are supported by moderate-quality evidence from observational studies and expert consensus, though predictive models remain speculative due to limited validation.

Looking ahead, advancements in biomarker identification and therapeutic development may clarify Long-COVID's prognosis by 2030, potentially informing broader pandemic preparedness strategies [44]. Speculatively, scalable diagnostic tools and precision therapies could reduce the long-term burden of Long-COVID, but these projections rely on low-quality evidence rooted in expert opinion, necessitating cautious interpretation. Increased funding and interdisciplinary collaboration are critical to accelerate progress, particularly in underrepresented regions and populations.

**Table 1: Timeline of Key Discoveries**

| Year | Key Discovery/Event |
|---|---|
| 2019 | SARS-CoV-2 identified in Wuhan; initial cases reported [48]. |
| 2020 | First reports of "long-haulers" with persistent symptoms; CDC notes early U.S. spread [3]. |
| 2021 | WHO formalizes Long-COVID definition; studies link to organ damage [49]. |
| 2022 | Mechanisms like viral persistence proposed; overlap with ME/CFS noted [50]. |
| 2023 | Major reviews on immune dysregulation; prevalence estimates stabilize at 10-30% [18]. |
| 2023 | Meta-analyses on subtypes; ongoing trials for therapies like tirzepatide [51]. |
| 2024 | NASEM defines as chronic systemic disease; vaccination's protective role confirmed [5]. |

## Conclusion

Long-COVID represents a complex, multisystem condition driven by immune dysregulation, vascular pathology, and persistent viral effects, with profound impacts on individual quality of life and societal health systems. Advances in symptom-focused management, including rehabilitation and multidisciplinary care, have improved patient outcomes, yet significant gaps remain in understanding its pathophysiology, establishing diagnostic biomarkers, and developing curative therapies. Robust, well-funded research efforts, prioritizing standardized definitions, longitudinal studies, and equitable public health strategies, are essential to address these challenges and mitigate Long-COVID's long-term burden, while informing preparedness for future pandemics.

## References


1. Centers for Disease Control and Prevention. Long COVID or post-COVID conditions. Available from: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html
2. World Health Organization. Post COVID-19 condition (Long COVID). Available from: https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition
3. Callard F, Perego E. How and why patients made Long COVID. Soc Sci Med. 2021;268:113426. DOI: https://doi.org/10.1016/j.socscimed.2020.113426 PMid:33199035 PMCid:PMC7539940
4. Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute COVID-19 in primary care. BMJ. 2020;370:m3026. DOI: https://doi.org/10.1136/bmj.m3026 PMid:32784198
5. National Academies of Sciences, Engineering, and Medicine. A Long COVID definition: A chronic, systemic disease state with profound consequences. Washington (DC): National Academies Press; 2024.
6. Han Q, Zheng B, Daines L, Sheikh A. Long-term sequelae of COVID-19: A systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms. Pathogens. 2022;11(2):269. DOI: https://doi.org/10.3390/pathogens11020269 PMid:35215212 PMCid:PMC8875269
7. Ford ND, Slaughter D, Edwards D, et al. Long COVID and significant activity limitation among adults, by age - United States, June 1-13, 2022, to June 7-19, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(32):866-870. DOI: https://doi.org/10.15585/mmwr.mm7232a3 PMid:37561665 PMCid:PMC10415000
8. Fernández-de-Las-Peñas C, Notarte KI, Peligro PJ, et al. Long-COVID symptoms in individuals infected with different SARS-CoV-2 variants of concern: A systematic review and meta-analysis. Viruses. 2022;14(11):2454. DOI: https://doi.org/10.3390/v14112454 PMid:36366552 PMCid:PMC9699601
9. Wulf Hanson S, Abbafati C, Aerts JG, et al. A global systematic analysis of the occurrence, severity, and recovery pattern of long COVID in 2020 and 2021. medRxiv. 2022; DOI: https://doi.org/10.1101/2022.05.26.22275532
10. Behnood SA, Shafran R, Bennett SD, et al. Persistent symptoms following SARS-CoV-2 infection amongst children and young people: A meta-analysis of controlled and uncontrolled studies. J Infect. 2022;84(2):158-170. DOI: https://doi.org/10.1016/j.jinf.2021.11.011 PMid:34813820 PMCid:PMC8604800

11. Tsampasian V, Elghazaly H, Chattopadhyay R, et al. Risk factors associated with post-COVID-19 condition: A systematic review and meta-analysis. JAMA Intern Med. 2023;183(6):566-580. DOI: https://doi.org/10.1001/jamainternmed.2023.0750 PMid:36951832 PMCid:PMC10037203

12. Byambasuren O, Stehlik P, Clark J, et al. Effect of COVID-19 vaccination on long COVID: Systematic review. BMJ Med. 2023;2(1):e000385. DOI: https://doi.org/10.1136/bmjmed-2022-000385 PMid:36936268 PMCid:PMC9978692

13. Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with Delta versus Omicron variants of SARS-CoV-2. Lancet. 2022;399(10343):2263-2264. DOI: https://doi.org/10.1016/S0140-6736(22)00941-2 PMid:35717982

14. Perlis RH, Lunz Trujillo K, Safarpour A, et al. Community-based prevalence of long COVID in the United States: Analysis of a population-representative sample. medRxiv. 2023; doi:10.1101/2023.03.03.23286755

15. Adjaye-Gbewonyo D, Vahratian A, Perrine CG, Mullins J. Long COVID in adults: United States, 2022. NCHS Data Brief. 2023;(480):1-8. DOI: https://doi.org/10.15620/cdc:132417

16. Fernández-de-Las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V, et al. Defining post-COVID symptoms (post-acute COVID, long COVID, persistent post-COVID): An integrative classification. Int J Environ Res Public Health. 2021;18(5):2621. DOI: https://doi.org/10.3390/ijerph18052621 PMid:33807869

17. Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021;12:698169. DOI: https://doi.org/10.3389/fmicb.2021.698169 PMid:34248921 PMCid:PMC8260991

18. Castanares-Zapatero D, Chalon P, Kohn L, et al. Pathophysiology and mechanism of long COVID: A comprehensive review. Ann Med. 2022;54(1):1473-1487. DOI: https://doi.org/10.1080/07853890.2022.2076901 PMid:35594336 PMCid:PMC9132392

19. Chen C, Haupert SR, Zimmermann L, et al. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: A meta-analysis and systematic review. J Infect Dis. 2022;226(9):1593-1607. DOI: https://doi.org/10.1093/infdis/jiac136 PMid:35429399 PMCid:PMC9047189

20. Swank Z, Senussi Y, Manickas-Hill Z, et al. Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. Clin Infect Dis. 2023;76(3):e487-e490. DOI: https://doi.org/10.1093/cid/ciac722 PMid:36052466 PMCid:PMC10169416

21. Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23(2):210-216. DOI: https://doi.org/10.1038/s41590-021-01113-x PMid:35027728

22. Monje M, Iwasaki A. The neurobiology of long COVID. Neuron. 2022;110(21):3484-3496. DOI: https://doi.org/10.1016/j.neuron.2022.10.006 PMid:36288726 PMCid:PMC9537254

23. Pretorius E, Vlok M, Venter C, et al. Persistent clotting protein pathology in long COVID/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021;20(1):172. DOI: https://doi.org/10.1186/s12933-021-01359-7 PMid:34425843 PMCid:PMC8381139

24. Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nat Med. 2022;28(5):911-923. DOI: https://doi.org/10.1038/s41591-022-01810-6 PMid:35585196

25. Pairo-Castineira E, Clohisey S, Klaric L, et al. Genetic mechanisms of critical illness in COVID-19. Nature. 2021;591(7848):92-98. DOI: https://doi.org/10.1038/s41586-020-03065-y PMid:33307546

26. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Sci Rep. 2021;11(1):16144. DOI: https://doi.org/10.1038/s41598-021-95565-8 PMid:34373540 PMCid:PMC8352980

27. Komaroff AL, Bateman L. Will COVID-19 lead to myalgic encephalomyelitis/chronic fatigue syndrome? Front Med (Lausanne). 2021;7:606824. DOI: https://doi.org/10.3389/fmed.2020.606824 PMid:33537329 PMCid:PMC7848220

28. Torres-Castro R, Vasconcello-Castillo L, Alsina-Restoy X, et al. Respiratory function in patients post-infection by COVID-19: A systematic review and meta-analysis. Pulmonology. 2021;27(4):328-337. DOI: https://doi.org/10.1016/j.pulmoe.2020.10.013 PMid:33262076 PMCid:PMC7687368

29. Raman B, Bluemke DA, Lüscher TF, Neubauer S. Long COVID: Post-acute sequelae of COVID-19 with a cardiovascular focus. Eur Heart J. 2022;43(11):1157-1172. DOI: https://doi.org/10.1093/eurheartj/ehac031 PMid:35176758 PMCid:PMC8903393

30. Douaud G, Lee S, Alfaro-Almagro F, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604(7907):697-707. DOI: https://doi.org/10.1038/s41586-022-04569-5

31. Carfì A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603-605. DOI: https://doi.org/10.1001/jama.2020.12603 PMid:32644129 PMCid:PMC7349096

32. Kenny G, McCann K, O'Brien C, et al. Identification of distinct long COVID clinical phenotypes through cluster analysis of self-reported symptoms. Open Forum Infect Dis. 2022;9(4):ofac060. DOI: https://doi.org/10.1093/ofid/ofac060 PMid:35265728 PMCid:PMC8900926

33. Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. DOI: https://doi.org/10.1016/j.eclinm.2021.101019 PMid:34308300 PMCid:PMC8280690

34. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV; WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102-e107. DOI: https://doi.org/10.1016/S1473-3099(21)00703-9 PMid:34951953

35. Centers for Disease Control and Prevention. Evaluating and caring for patients with post-COVID conditions: Interim guidance. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-index.html

36. Klok FA, Boon GJAM, Barco S, et al. The Post-COVID-19 Functional Status scale: A tool to measure functional status over time after COVID-19. Eur Respir J. 2020;56(1):2001494. DOI: https://doi.org/10.1183/13993003.01494-2020 PMid:32398306 PMCid:PMC7236834

37. Crook H, Raza S, Nowell J, Young M, Edison P. Long COVID-mechanisms, risk factors, and management. BMJ. 2021;374:n1648. DOI: https://doi.org/10.1136/bmj.n1648 PMid:34312178

38. Yelin D, Moschopoulos CD, Margalit I, et al. ESCMID rapid guidelines for assessment and management of long COVID. Clin Microbiol Infect. 2022;28(7):955-972. DOI: https://doi.org/10.1016/j.cmi.2022.02.018 PMid:35182760 PMCid:PMC8849856

39. O'Mahoney LL, Routen A, Gillies C, et al. The prevalence and long-term health effects of long COVID among hospitalised and non-hospitalised populations: A systematic review and meta-analysis. EClinicalMedicine. 2023;55:101762. DOI: https://doi.org/10.1016/j.eclinm.2022.101762 PMid:36474804

40. McCarthy MW. Paxlovid as a potential treatment for long COVID. Expert Rev Anti Infect Ther. 2023;21(8):781-785. DOI: https://doi.org/10.1080/14656566.2023.2262387 PMid:37731377

41. Charfeddine S, Ibn Hadj Amor H, Jdidi J, et al. Long COVID 19 syndrome: Is it related to microcirculation and endothelial dysfunction? Insights from TUN-EndCOV study. Front Cardiovasc Med. 2021;8:745788. DOI: https://doi.org/10.3389/fcvm.2021.745758 PMid:34917659 PMCid:PMC8670225

42. Nurek M, Rayner C, Freyer A, et al. Recommendations for the recognition, diagnosis, and management of long COVID: A Delphi study. Br J Gen Pract. 2021;71(712):e815-e825. DOI: https://doi.org/10.3399/BJGP.2021.0265 PMid:34607799 PMCid:PMC8510689

43. Writing Committee for the REMAP-CAP Investigators. Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: A randomized clinical trial. JAMA. 2022;327(13):1247-1259. DOI: https://doi.org/10.1001/jama.2022.23257 PMid:36525245

44. Al-Aly Z, Topol EJ. Solving the puzzle of long COVID. Science. 2024;383(6685):830-832. DOI: https://doi.org/10.1126/science.adl0867 PMid:38386747

45. Ledford H. Long COVID treatments: Where are we at? Nature. 2023;611(7935):S18-S20.

46. Michelen M, Manoharan L, Elkheir N, et al. Characterising long COVID: A living systematic review. BMJ Glob Health. 2021;6(9):e005427. DOI: https://doi.org/10.1136/bmjgh-2021-005427 PMid:34580069

47. Topol EJ. AI in medicine: Where are we now and where are we going? Cell. 2023;186(12):2487-2489.

48. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733. DOI: https://doi.org/10.1056/NEJMoa2001017 PMid:31978945

49. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. World Health Organization; 2021. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1

50. Paul BD, Lemle MD, Komaroff AL, Snyder SH. Redox imbalance links COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome. Proc Natl Acad Sci U S A. 2021;118(34):e2024358118. DOI: https://doi.org/10.1073/pnas.2024358118 PMid:34400495 PMCid:PMC8403932

51. Fernández-de-Las-Peñas C, Ryan-Murua P, de-la-Llave-Rincón AI, et al. Serological biomarkers at hospital admission and hospitalization treatments are not related to long-COVID-19 syndrome in patients with SARS-CoV-2 infection. J Med Virol. 2023;95(11):e29211. DOI: https://doi.org/10.1002/jmv.29211